Isoliensinine

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funder: Natural Science Basic Research Program of Shaanxi Province

Animals1

Outcomes

Inflammation

downin mice1

1 study

Isoliensinine decreases inflammation in mice.
“Furthermore, ISL suppressed neuroinflammation by reducing hippocampal microglial activation and inhibiting the phosphorylation of p38 MAPK.”
Animalstibial surgeryhippocampus10 mg/kgdaily
Isoliensinine ameliorates postoperative neurocognitive disorder in aged mice by restoring hippocampal IGF-1 receptor signaling and suppressing oxidative stress and neuroinflammation
European journal of pharmacology6 Feb 2026

Latest

1 in 12 months

European Journal of Pharmacology9 Feb

Isoliensinine ameliorates postoperative neurocognitive disorder in aged mice by restoring hippocampal IGF-1 receptor signaling and suppressing oxidative stress and neuroinflammation

Experiments in miceInterventions

Paper

Isoliensinine

Outcomes

Latest

Isoliensinine ameliorates postoperative neurocognitive disorder in aged mice by restoring hippocampal IGF-1 receptor signaling and suppressing oxidative stress and neuroinflammation

Related